---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-126753"
form_type: "8-K"
ticker: "RANI"
cik: "0001856725"
company_name: "Rani Therapeutics Holdings, Inc."
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:37:26.670180+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Rani Therapeutics Q3 net loss $12.7M; cash $30.4M extended into Q3 2025

## Summary
- Net loss of $12.7M for Q3 2024, compared to $18.3M in Q3 2023; includes $4.1M stock-based comp.
- Cash, equivalents and marketable securities $30.4M as of Sep 30, 2024; runway extended into Q3 2025.
- Completed two equity offerings for total gross proceeds of ~$20.0M in July and October 2024.
- New preclinical PK data supports oral delivery of GLP-1/GIP/glucagon triagonist via RaniPill platform.
- Phase 1 trial of RT-114 (GLP-1/GLP-2 dual agonist) for obesity expected to start in 2025.

## SEC filing metadata
- accession: 0000950170-24-126753
- form_type: 8-K
- ticker: RANI
- cik: 0001856725
- company_name: Rani Therapeutics Holdings, Inc.
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1856725/000095017024126753/0000950170-24-126753-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1856725/000095017024126753/rani-20241114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-126753
- JSON: https://secwatch.observer/filing/0000950170-24-126753.json
- Plain text: https://secwatch.observer/filing/0000950170-24-126753.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.